Teva Pharma sees lower 2024 profit but higher sales after large Q4 beat

By Steven Scheer

JERUSALEM (Reuters) -Teva Pharmaceuticals forecast lower profit but higher sales this year after a strong 2023 fourth quarter boosted by a large upfront payment from Sanofi as part of a collaboration to develop a treatment for inflammatory bowel disease.

The world's largest generic drugmaker also said on Wednesday it would divest its active pharmaceutical ingredient (API) unit in a deal expected to be completed in 2025.

Teva's focus is "growing our innovative business, our innovative pipeline and generics business. We don't want to spread ourselves too thin," CEO Richard Francis told Reuters, noting the API market is worth $85 billion globally.

Teva said it earned $1.00 per diluted share excluding one-time items in the October-December quarter, up from 71 cents per share a year earlier. Revenue rose 15% to $4.5 billion.

Its New York shares jumped 6.6% to $12.51 by 1819 GMT.

Analysts had forecast earnings of 77 cents a share ex-items for the Israel-based company on revenue of $4.01 billion, LSEG I/B/E/S data showed.

Sanofi, a leader in immunology, in October said it would invest $1.5 billion in the development of Teva's anti-TL1A drug with Teva receiving an upfront payment of $500 million. The drug is still in phase 2 trials, with interim results not expected until the second half of 2024.

Teva estimated 2024 group adjusted EPS of $2.20-$2.50, lower than $2.56 in 2023 and compared with analysts' expectations of $2.42. It foresees 2024 revenue of $15.7-$16.3 billion, versus $15.8 billion last year and expectations of $15.6 billion.

Francis told an analysts' conference call that 2023 was a transformation year for Teva as it accomplished a goal of returning to growth, which it expects to accelerate between 2025 and 2027 given its pipeline of products.

"We are gaining momentum," he said. "And now it's about executing as we did in 2023 in 2024."

BET ON OWN BRANDS

Francis said the Israel-Hamas war was not having any material impact on its business, with just a small amount of revenue and production in Israel. He added that Teva was using contingency plans to maintain a supply chain in the wake of tensions in Red Sea shipping lanes.

Teva has struggled since 2016 to recover from the loss of exclusivity to its multiple sclerosis drug Copaxone, and to cut $35 billion of debt as it fought a spate of lawsuits alleging it helped fuel the U.S. opioid epidemic.

But it has started to show signs of recovery and is betting a trio of its branded drugs - Austedo, migraine product Ajovy and schizophrenia drug Uzedy - will help it bounce back. Teva also has a number of biosimilars - copies of high-priced drugs - in its pipeline and its net debt is down to $16.6 billion.

After hitting revenue of $1.2 billion in 2023, Austedo is projected to reach $1.5 billion this year and $2.5 billion by 2027. Ajovy is expected to reap revenue of $500 million while the just-launched Uzedy is forecast to generate $80 million this year.

Francis said Teva was still planning on launching a biosimilar of AbbVie's blockbuster arthritis drug Humira this year, even as AbbVie managed to hold on to a vast majority of the Humira market last year despite nine biosimilars launching.

(Reporting by Steven Scheer in Jerusalem; Additional reporting by Patrick Wingrove in New York; Editing by Jason Neely and Emelia Sithole-Matarise)